Stillwater Capital Advisors LLC Raises Stake in Johnson & Johnson (JNJ)

Stillwater Capital Advisors LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 17.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,918 shares of the company’s stock after acquiring an additional 15,277 shares during the quarter. Johnson & Johnson makes up 3.4% of Stillwater Capital Advisors LLC’s holdings, making the stock its 6th biggest holding. Stillwater Capital Advisors LLC’s holdings in Johnson & Johnson were worth $14,380,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Landmark Financial Advisors LLC increased its holdings in Johnson & Johnson by 0.4% in the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock worth $259,000 after purchasing an additional 7 shares in the last quarter. Paradigm Financial Advisors LLC increased its holdings in Johnson & Johnson by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock worth $350,000 after purchasing an additional 9 shares in the last quarter. Premier Asset Management LLC increased its holdings in Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after purchasing an additional 12 shares in the last quarter. Lbmc Investment Advisors LLC increased its holdings in Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after purchasing an additional 14 shares in the last quarter. Finally, Halbert Hargrove Russell LLC increased its holdings in Johnson & Johnson by 0.4% in the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after purchasing an additional 15 shares in the last quarter. Institutional investors own 67.21% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of equities research analysts have weighed in on JNJ shares. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a report on Monday, January 22nd. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Wells Fargo reissued an “outperform” rating and issued a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Finally, JPMorgan Chase & Co. cut Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $146.06.

Johnson & Johnson stock opened at $125.10 on Friday. The stock has a market capitalization of $335,631.06, a P/E ratio of 17.14, a P/E/G ratio of 1.99 and a beta of 0.77. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a 1 year low of $120.95 and a 1 year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. The company had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. Johnson & Johnson’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.58 earnings per share. research analysts forecast that Johnson & Johnson will post 8.11 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th were given a dividend of $0.84 per share. The ex-dividend date was Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s payout ratio is 861.54%.

In related news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now owns 357,906 shares of the company’s stock, valued at $46,477,673.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.19% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This article was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3299133/stillwater-capital-advisors-llc-raises-stake-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mountain Province Diamonds  and Trxade Group  Head-To-Head Contrast
Mountain Province Diamonds and Trxade Group Head-To-Head Contrast
Contrasting SEI Investments  & Its Rivals
Contrasting SEI Investments & Its Rivals
Celestica  & Flex  Financial Contrast
Celestica & Flex Financial Contrast
Zacks Investment Research Upgrades Metso  to “Buy”
Zacks Investment Research Upgrades Metso to “Buy”
$1.55 Billion in Sales Expected for Fifth Third Bank  This Quarter
$1.55 Billion in Sales Expected for Fifth Third Bank This Quarter
Zacks Investment Research Downgrades Trend Micro  to Hold
Zacks Investment Research Downgrades Trend Micro to Hold


© 2006-2018 Ticker Report. Google+.